Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Foveal avascular zone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Foveal avascular zone. Displaying page 1 of 1.
    EudraCT Number: 2005-001722-92 Sponsor Protocol Number: 1 Start Date*: 2005-10-12
    Sponsor Name:The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery
    Full Title: Systemic Bevacizumab (Avastin®) Therapy for Exudative Neovascular Age-Related Macular Degeneration (BEAT-AMD-Study)
    Medical condition: Age related macular degeneration (AMD) patients with fibrovascular pigment epithelium detachment (PED), subfoveal choroidal neovascularisations (CNV) extending under the geometric center of the fov...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007232-18 Sponsor Protocol Number: CRFB002AHU04T Start Date*: 2009-03-19
    Sponsor Name:University of Szeged, Medical and Pharmaceutical Center, Department of Ophthalmology [...]
    1. University of Szeged, Medical and Pharmaceutical Center, Department of Ophthalmology
    2. Semmelweis University Department of Ophthalmology
    3. Cholnoky F. County Hospital Veszprém Department of Ophthalmology
    Full Title: Comparison of the effect of intravitreal ranibizumab injections compared to macular grid-pattern laser therapy for the symptomatic treatment of diabetic macular edema (a randomized, controlled, pha...
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017540-13 Sponsor Protocol Number: Start Date*: 2010-07-27
    Sponsor Name:Clinical Trials and Research Governance
    Full Title: A Phase IV Open-Labelled Prospective Pilot Study of Intravitreal Macugen (pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME study)
    Medical condition: Ischaemic diabetic macular oedema.
    Disease: Version SOC Term Classification Code Term Level
    12 10057915 diabetic macular oedema SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-005945-39 Sponsor Protocol Number: HLS03/2007 Start Date*: 2008-01-30
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Phase II open label study of Pegaptanib sodium on patients with subfoveal choroidal neovascularization caused by pathologic myopia.
    Medical condition: Patients with choroidal neovascularization secondary to pathologic myopia.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10060823 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002977-33 Sponsor Protocol Number: Luc01AKSI Start Date*: 2006-06-22
    Sponsor Name:University Eye Hospital
    Full Title: Safety and efficacy of intravitreal injections of ranibizumab/Lucentis in combination with verteporfin photodynamic therapy (PDT) in patients with choroidal neovascularisation (CNV) secondary to ag...
    Medical condition: Age related macular degeneration (AMD) is the leading cause of blindness in individuals older than 50 years in the developed world. Eighty to ninety percent of rapid and severe vision loss due to A...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006290-90 Sponsor Protocol Number: AU-06102G Start Date*: 2008-10-10
    Sponsor Name:Society (Institute) for clinical research
    Full Title: Subretinal Macugen for neovascular age-related macular degeneration (SUMANA)
    Medical condition: Neovascular (exudative) age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007476-19 Sponsor Protocol Number: OP/2008/2980 Start Date*: 2009-09-24
    Sponsor Name:University Hospitals Bristol NHS Trust
    Full Title: A prospective case series of Ranibizumab for the treatment of inflammatory and idiopathic choroidal neovascular membranes.
    Medical condition: idiopathic and inflammatory choroidal neovascular membranes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003304-20 Sponsor Protocol Number: OKHN1006 Start Date*: 2012-07-02
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: Randomised Controlled Trial of Intravitreal therapy with Avastin compared to Observation in Patients with Diabetic Ischaemic Macular Oedema ‘The DIME study’
    Medical condition: Ischaemic Diabetic Macular Oedema
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    14.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    14.1 10015919 - Eye disorders 10012688 Diabetic retinal oedema PT
    14.1 10015919 - Eye disorders 10012661 Diabetic eye disease PT
    14.1 10015919 - Eye disorders 10054372 Diabetic retinal edema LLT
    14.1 10015919 - Eye disorders 10038925 Retinopathy diabetic LLT
    14.1 10015919 - Eye disorders 10057915 Diabetic macular oedema LLT
    14.1 10014698 - Endocrine disorders 10012657 Diabetic complications ophthalmic HLT
    14.1 10015919 - Eye disorders 10054109 Non-proliferative diabetic retinopathy LLT
    14.1 10014698 - Endocrine disorders 10012653 Diabetic complications HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000379-41 Sponsor Protocol Number: RLBUHT3407 Start Date*: 2007-05-22
    Sponsor Name:Royal Liverpool & Broadgreen University hospital
    Full Title: Liverpool Avastin Dose Response and Retreatment Study
    Medical condition: Exudative senile macular degeneration of the retina
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000847-89 Sponsor Protocol Number: BELS1001 Start Date*: 2007-06-27
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: Full Title of Study: Diabetic macular oedema: a prospective randomised trial of management with intravitreal bevacizumab (Avastin) versus conventional laser therapy
    Medical condition: Diabetic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006131-53 Sponsor Protocol Number: AU-06104G Start Date*: 2007-08-02
    Sponsor Name:Society (institute) for clinical research
    Full Title: Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study
    Medical condition: Macular edema secondary to branch retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025415 Macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001869-41 Sponsor Protocol Number: OKHN1005 Start Date*: 2011-08-24
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: An exploratory study of ranibizumab (Lucentis) for treatment of uveitic patients with refractory cystoid macular oedema. 'The LIMO study'
    Medical condition: Uveitic Macular Oedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10046851 Uveitis PT
    20.1 10015919 - Eye disorders 10058202 Cystoid macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003661-17 Sponsor Protocol Number: SS01 Start Date*: 2012-11-09
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: A Multicentre Prospective Open-label Randomised Clinical Trial Comparing the Efficacy of Fixed versus PRN dosing of 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) in patie...
    Medical condition: Diabetic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001235-30 Sponsor Protocol Number: MSI-1256F-302 Start Date*: 2005-10-26
    Sponsor Name:Genaera Corporation
    Full Title: A Phase 3 Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Re...
    Medical condition: Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023900-29 Sponsor Protocol Number: MAF-AGN-OPH-RET-004 Start Date*: 2011-08-23
    Sponsor Name:Allergan Pharmaceuticals Ireland
    Full Title: A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex® Versus Lucentis® in Patients with Branch Retinal Vein Occlusion
    Medical condition: Macula oedema secondary to branch retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10025415 Macular oedema PT
    17.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000243-24 Sponsor Protocol Number: MD7114987 Start Date*: 2011-06-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: An open-label, phase 2a study to evaluate pazopanib eye drops administered for 12 weeks to patients with neovascular agerelated macular degeneration
    Medical condition: Age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000031-27 Sponsor Protocol Number: Start Date*: 2013-03-20
    Sponsor Name:Moorfields Eye Hospital
    Full Title: Intravitreal Ranibizumab (Lucentis) Therapy in Patients with Diabetic Ischaemic Macular Oedema (DIME)
    Medical condition: Ischaemic Diabetic Macular Oedema
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10057915 Diabetic macular oedema LLT
    14.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    14.1 10015919 - Eye disorders 10012688 Diabetic retinal oedema PT
    14.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    14.1 10015919 - Eye disorders 10054372 Diabetic retinal edema LLT
    14.1 10015919 - Eye disorders 10054109 Non-proliferative diabetic retinopathy LLT
    14.1 10015919 - Eye disorders 10012661 Diabetic eye disease PT
    14.1 10015919 - Eye disorders 10038925 Retinopathy diabetic LLT
    14.1 10014698 - Endocrine disorders 10012653 Diabetic complications HLGT
    14.1 10014698 - Endocrine disorders 10012657 Diabetic complications ophthalmic HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA